NextCure (NXTC) Short Interest Ratio & Short Volume $0.47 -0.03 (-5.64%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$0.45 -0.01 (-3.09%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NextCure Short Interest DataNextCure (NXTC) has a short interest of 35,800 shares, representing 0.16% of the float (the number of shares available for trading by the public). This marks a -39.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 101,487 shares to cover all short positions.Current Short Interest35,800 sharesPrevious Short Interest59,000 sharesChange Vs. Previous Month-39.32%Dollar Volume Sold Short$11,910.66Short Interest Ratio0.3 Days to CoverLast Record DateApril 15, 2025Outstanding Shares28,050,000 sharesFloat Size21,840,000 sharesShort Percent of Float0.16%Today's Trading Volume246,727 sharesAverage Trading Volume101,487 sharesToday's Volume Vs. Average243% Short Selling NextCure? Sign up to receive the latest short interest report for NextCure and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNXTC Short Interest Over TimeNXTC Days to Cover Over TimeNXTC Percentage of Float Shorted Over Time NextCure Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202535,800 shares $11,910.66 -39.3%0.2%0.3 $0.33 3/31/202559,000 shares $28,337.70 -10.3%0.3%0.6 $0.48 3/15/202565,800 shares $45,329.62 -2.5%0.3%0.6 $0.69 2/28/202567,500 shares $52,582.50 +14.0%0.3%0.4 $0.78 2/15/202559,200 shares $44,832.16 +7.6%0.3%0.4 $0.76 1/31/202555,000 shares $44,264.00 +33.5%0.3%0.3 $0.80 1/15/202541,200 shares $32,506.80 -56.6%0.2%0.3 $0.79 12/31/202494,900 shares $73,167.90 +88.3%0.5%0.7 $0.77 12/15/202450,400 shares $54,432.00 No Change0.2%0.5 $1.08 11/30/202450,400 shares $58,968.00 +12.3%0.2%0.6 $1.17 Get the Latest News and Ratings for NXTC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. 11/15/202444,900 shares $58,819.00 -32.1%0.2%1 $1.31 10/31/202466,100 shares $87,582.50 -10.4%0.3%2.1 $1.33 10/15/202473,800 shares $103,320.00 -3.0%0.4%2.3 $1.40 9/30/202476,100 shares $104,257.00 +15.7%0.4%2.1 $1.37 9/15/202465,800 shares $92,120.00 -15.4%0.3%1.5 $1.40 8/31/202477,800 shares $114,366.00 -2.9%0.4%1.6 $1.47 8/15/202480,100 shares $124,956.00 -7.0%0.4%1.4 $1.56 7/31/202486,100 shares $139,482.00 +2.4%0.4%1.2 $1.62 7/15/202484,100 shares $140,447.00 -15.0%0.4%0.9 $1.67 6/30/202498,900 shares $157,251.00 +41.1%0.5%1 $1.59 6/15/202470,100 shares $112,160.00 -19.4%0.3%0.5 $1.60 5/31/202487,000 shares $133,980.00 -3.9%0.4%0.4 $1.54 5/15/202490,500 shares $150,230.00 -19.5%0.4%0.3 $1.66 4/30/2024112,400 shares $136,004.00 -0.7%0.5%0.4 $1.21 4/15/2024113,200 shares $189,044.00 -88.6%0.5%0.4 $1.67 3/31/2024993,800 shares $2.22 million +18.4%4.7%3.8 $2.23 3/15/2024839,700 shares $1.22 million +579.9%4.0%3.7 $1.45 2/29/2024123,500 shares $213,655.00 +4.7%0.6%0.7 $1.73 2/15/2024118,000 shares $166,380.00 +8.4%0.6%1.1 $1.41 1/31/2024108,900 shares $132,858.00 -11.8%0.6%1.2 $1.22 1/15/2024123,400 shares $143,144.00 -42.8%0.6%1.3 $1.16 12/31/2023215,800 shares $246,012.00 -6.2%1.1%2.2 $1.14 12/15/2023230,000 shares $255,300.00 +17.3%1.2%2.3 $1.11 11/30/2023196,100 shares $231,398.00 -0.6%1.0%3.2 $1.18 11/15/2023197,200 shares $246,500.00 +0.1%1.0%3.7 $1.25 10/31/2023197,000 shares $202,910.00 -1.5%1.0%3.7 $1.03 10/15/2023199,900 shares $249,875.00 -13.2%1.0%4.7 $1.25 9/30/2023230,300 shares $297,087.00 +11.9%1.2%6.4 $1.29 9/15/2023205,900 shares $284,142.00 -2.5%1.1%4.8 $1.38 8/31/2023211,100 shares $308,206.00 +0.3%1.1%5.2 $1.46Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 8/15/2023210,500 shares $357,850.00 -1.5%1.1%4.8 $1.70 7/31/2023213,800 shares $367,736.00 -3.5%1.1%4.2 $1.72 7/15/2023221,600 shares $390,016.00 -17.9%1.1%4.1 $1.76 6/30/2023269,800 shares $485,640.00 +7.2%1.4%4.7 $1.80 6/15/2023251,700 shares $420,339.00 +6.6%1.3%4.7 $1.67 5/31/2023236,100 shares $406,092.00 -12.2%1.2%3.9 $1.72 5/15/2023268,900 shares $457,856.03 +4.3%1.4%3.8 $1.70 4/30/2023257,800 shares $389,278.00 -4.1%1.3%3.4 $1.51 4/15/2023268,700 shares $403,050.00 -15.4%1.4%3.2 $1.50 3/31/2023317,700 shares $470,196.00 -3.8%1.6%3.5 $1.48 3/15/2023330,300 shares $518,571.00 -6.9%1.7%2.1 $1.57 2/28/2023354,900 shares $550,095.00 +14.7%1.8%2.1 $1.55 2/15/2023309,500 shares $485,915.00 -7.3%1.6%1.7 $1.57 1/31/2023333,900 shares $557,613.00 -0.2%1.9%1.7 $1.67 1/15/2023334,700 shares $538,867.00 -9.5%1.9%1.7 $1.61 12/30/2022369,800 shares $521,418.00 -12.5%2.1%1.9 $1.41 12/15/2022422,600 shares $549,380.00 +3.4%2.4%2.5 $1.30 11/30/2022408,600 shares $576,126.00 -4.3%2.3%3.5 $1.41 11/15/2022426,800 shares $708,488.00 -10.2%2.4%4 $1.66 10/31/2022475,300 shares $1.19 million -11.6%2.7%4.1 $2.50 10/15/2022537,400 shares $1.45 million -8.6%3.3%5.4 $2.70 9/30/2022587,800 shares $1.62 million -3.2%3.6%5.5 $2.75 9/15/2022607,100 shares $2.31 million -21.6%3.7%4.8 $3.81 8/31/2022774,000 shares $3.17 million -2.9%4.7%5.2 $4.10 8/15/2022797,000 shares $4.14 million +9.9%4.8%4.5 $5.19 7/31/2022725,100 shares $3.12 million -9.4%4.4%4.1 $4.30 7/15/2022800,000 shares $3.66 million -4.9%4.9%4.6 $4.57 6/30/2022841,200 shares $3.95 million +13.1%5.1%5 $4.70 6/15/2022743,900 shares $3.37 million +21.4%4.5%4.5 $4.53 5/31/2022612,700 shares $2.39 million -4.0%3.7%4.3 $3.90 5/15/2022638,500 shares $2.26 million +1.5%3.9%5.4 $3.54 4/30/2022629,300 shares $2.62 million +0.4%3.8%5.7 $4.16 4/15/2022626,800 shares $3.14 million +2.9%3.8%4.9 $5.01 3/31/2022608,900 shares $2.96 million -5.8%3.7%4.5 $4.86 3/15/2022646,200 shares $3.15 million +2.1%N/A4.4 $4.88 2/28/2022633,000 shares $3.10 million -7.6%3.8%3.8 $4.90 2/15/2022685,100 shares $3.59 million -10.1%4.1%3.7 $5.24 1/31/2022761,900 shares $4.24 million -1.0%4.7%3.2 $5.57 1/15/2022769,700 shares $4.37 million +0.7%4.8%3 $5.68 12/31/2021764,600 shares $4.59 million +11.0%4.8%2.9 $6.00 12/15/2021688,900 shares $4.02 million +3.6%4.3%2.3 $5.83 11/30/2021664,800 shares $4.16 million +16.4%4.1%2.3 $6.25 11/15/2021571,000 shares $3.53 million -6.3%3.6%2.1 $6.18 10/29/2021609,100 shares $5.01 million -8.4%3.9%2.3 $8.22 10/15/2021665,200 shares $5.81 million -15.2%4.3%2.7 $8.73 9/30/2021784,700 shares $5.29 million -4.9%5.1%3.4 $6.74 9/15/2021825,300 shares $6.01 million +4.3%5.3%3.3 $7.28 8/31/2021791,300 shares $6.03 million -15.4%5.1%3.1 $7.62 8/13/2021934,800 shares $6.74 million +0.7%6.0%3.3 $7.21 7/30/2021928,000 shares $6.43 million -9.9%6.0%3.4 $6.93Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 7/15/20211,030,000 shares $7.42 million +49.8%5.7%3.7 $7.20 6/30/2021687,800 shares $5.52 million -37.5%3.8%2.4 $8.03 6/15/20211,100,000 shares $8.95 million +0.9%6.0%4.6 $8.14 5/28/20211,090,000 shares $8.56 million +5.8%6.0%4.9 $7.85 5/14/20211,030,000 shares $8.25 million -1.0%5.7%4.8 $8.01 4/30/20211,040,000 shares $9.45 million -29.3%5.7%4.6 $9.09 4/15/20211,470,000 shares $13.88 million +1.4%8.1%6.9 $9.44 3/31/20211,450,000 shares $14.22 million -5.2%8.0%6.7 $9.81 3/15/20211,530,000 shares $19.39 million -3.2%8.4%5.5 $12.67 2/26/20211,580,000 shares $18.26 million -18.6%8.7%4.6 $11.56 2/12/20211,940,000 shares $26.93 million +5.4%10.7%5.3 $13.88 1/29/20211,840,000 shares $22.41 million +155.3%10.1%4.8 $12.18 1/15/2021720,800 shares $9.42 million -22.1%4.2%1.8 $13.07 12/31/2020925,100 shares $10.27 million -17.4%5.3%2.4 $11.10 12/15/20201,120,000 shares $13.78 million -32.1%6.5%2.6 $12.30 11/30/20201,650,000 shares $17.13 million +50.0%9.6%4.4 $10.38 11/15/20201,100,000 shares $11.61 million -42.1%6.4%2.9 $10.55 10/30/20201,900,000 shares $19.78 million +6.7%11.1%4.7 $10.41 10/15/20201,780,000 shares $20.74 million -9.6%11.0%3.3 $11.65 9/30/20201,970,000 shares $17.34 million -1.0%N/A2.3 $8.80 9/15/20201,990,000 shares $18.23 million +1.0%12.2%2.3 $9.16 8/31/20201,970,000 shares $17.71 million +8.8%12.1%2.3 $8.99 8/14/20201,810,000 shares $16.51 million -19.2%11.2%2.1 $9.12 7/31/20202,240,000 shares $19.98 million +8.7%13.8%2.8 $8.92 7/15/20202,060,000 shares $18.70 million -2.8%12.7%3.1 $9.08 6/30/20202,120,000 shares $47.04 million +21.8%13.1%5.9 $22.19 6/15/20201,740,000 shares $42.49 million +41.5%10.7%5.8 $24.42 5/29/20201,230,000 shares $38.39 million +2.5%7.6%4.5 $31.21 5/15/20201,200,000 shares $42.58 million -4.8%7.4%5.2 $35.48 NXTC Short Interest - Frequently Asked Questions What is NextCure's current short interest? Short interest is the volume of NextCure shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 35,800 shares of NXTC short. 0.16% of NextCure's shares are currently sold short. Learn More on NextCure's current short interest. Which institutional investors are shorting NextCure? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NextCure: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for NextCure? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.16% of NextCure's floating shares are currently sold short. Is NextCure's short interest increasing or decreasing? NextCure saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 35,800 shares, a decline of 39.3% from the previous total of 59,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NextCure's float size? NextCure currently has issued a total of 28,050,000 shares. Some of NextCure's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NextCure currently has a public float of 21,840,000 shares. How does NextCure's short interest compare to its competitors? 0.16% of NextCure's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to NextCure: Connect Biopharma Holdings Limited (0.15%), Mersana Therapeutics, Inc. (9.23%), Spero Therapeutics, Inc. (1.54%), Tenaya Therapeutics, Inc. (6.54%), OKYO Pharma Limited (0.63%), Anebulo Pharmaceuticals, Inc. (0.19%), Aadi Bioscience, Inc. (6.58%), Applied Therapeutics, Inc. (15.14%), bluebird bio, Inc. (5.24%), Coeptis Therapeutics Holdings, Inc. (1.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short NextCure stock? Short selling NXTC is an investing strategy that aims to generate trading profit from NextCure as its price is falling. NXTC shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NextCure? A short squeeze for NextCure occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NXTC, which in turn drives the price of the stock up even further. How often is NextCure's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NXTC, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Connect Biopharma Short Interest Data Mersana Therapeutics Short Interest Data Spero Therapeutics Short Interest Data Tenaya Therapeutics Short Interest Data OKYO Pharma Short Interest Data Anebulo Pharmaceuticals Short Interest Data Aadi Bioscience Short Interest Data Applied Therapeutics Short Interest Data bluebird bio Short Interest Data Coeptis Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NXTC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
